Cancer stem cell

Results: 652



#Item
1Laboratory Investigation, 970–982 & 2013 USCAP, Inc All rights reserved $32.00 PATHOBIOLOGY IN FOCUS Patient-derived xenografts, the cancer stem cell

Laboratory Investigation, 970–982 & 2013 USCAP, Inc All rights reserved $32.00 PATHOBIOLOGY IN FOCUS Patient-derived xenografts, the cancer stem cell

Add to Reading List

Source URL: www.abbvie.com

Language: English - Date: 2018-07-20 14:49:13
    224th NSW Stem Cell Network Workshop Stem Cells and Cancer Darlington Centre City Rd, Sydney Wednesday, April 6th, 2016

    24th NSW Stem Cell Network Workshop Stem Cells and Cancer Darlington Centre City Rd, Sydney Wednesday, April 6th, 2016

    Add to Reading List

    Source URL: www.stemcellnetwork.org.au

    Language: English - Date: 2016-04-11 20:16:04
      3Guideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Car

      Guideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Car

      Add to Reading List

      Source URL: www.childrensoncologygroup.org

      Language: English - Date: 2017-12-18 08:31:20
        4A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R,

        A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R,

        Add to Reading List

        Source URL: s3.amazonaws.com

        - Date: 2014-09-25 16:14:56
          5Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in

          Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in

          Add to Reading List

          Source URL: posters.omed.s3.amazonaws.com

          - Date: 2015-06-12 10:36:45
            6Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain

            Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain

            Add to Reading List

            Source URL: posters.omed.s3.amazonaws.com

            - Date: 2015-11-04 11:34:18
              7A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years)

              A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years)

              Add to Reading List

              Source URL: posters.omed.s3.amazonaws.com

              - Date: 2016-01-22 10:42:40
                8A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer 1Hidalgo Patient Demographics (n=47) DEM + GEM

                A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer 1Hidalgo Patient Demographics (n=47) DEM + GEM

                Add to Reading List

                Source URL: s3.amazonaws.com

                - Date: 2014-09-25 16:14:56
                  9Dual targeting of the DLL4 and VEGF pathways with a bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency Wan-Ching Yen, Marcus M. Fischer, Gretchen Argast, Breanna Wallace, Min Wan

                  Dual targeting of the DLL4 and VEGF pathways with a bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency Wan-Ching Yen, Marcus M. Fischer, Gretchen Argast, Breanna Wallace, Min Wan

                  Add to Reading List

                  Source URL: posters.omed.s3.amazonaws.com

                  - Date: 2015-11-04 11:34:26
                    10Safety and early evidence of activity of a first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with selected solid tumors A.

                    Safety and early evidence of activity of a first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with selected solid tumors A.

                    Add to Reading List

                    Source URL: s3.amazonaws.com

                    - Date: 2014-11-19 14:29:45